These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: MCV vaccination in the presence of vaccine-associated Guillain-Barré Syndrome risk: a decision analysis approach.
    Author: Cho BH, Clark TA, Messonnier NE, Ortega-Sanchez IR, Weintraub E, Messonnier ML.
    Journal: Vaccine; 2010 Jan 08; 28(3):817-22. PubMed ID: 19879992.
    Abstract:
    The study evaluates the benefits of meningococcal conjugate vaccine (MCV4) vaccination against the burden of vaccine-associated Guillain-Barré Syndrome (GBS) using simulation. An 11-year-old cohort was followed over an 8-year period in a simulation model Table 3 Figs. 1 and 2 to estimate health outcomes to assist decision makers in setting policy. Applying a 3% discount rate, MCV4 vaccination would save 2397 quality-adjusted life years (QALYs) while vaccine-attributable GBS could result in 5 QALYs lost. Based on the result, MCV4 vaccination is strongly favored despite possible vaccine-associated GBS risk.
    [Abstract] [Full Text] [Related] [New Search]